In vivo efficacy of enabling formulations based on hydroxypropyl-β-cyclodextrins, micellar preparation, and liposomes for the lipophilic cannabinoid CB2 agonist, MDA7

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 352-364

  Astruc Diaz, Fanny ^a,b   Mcdaniel, Steven W ^a   Xu, Jijun J ^c   Parola, Stéphane ^b   Brown, David L ^c   Naguib, Mohamed ^c   Diaz, Philippe ^a  

^a UNIVERSITY OF MONTANA   (United States)

^b UNIVERSITÉ DE LYON   (France)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bioavailability; Chirality; CNS; Complexation; Cyclodextrins; Liposomes; Micelle

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CANNABINOID 2 RECEPTOR AGONIST; LIPOSOME; MDA 7; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG SOLUBILITY; ELECTROSPRAY MASS SPECTROMETRY; ENANTIOMER; IN VIVO STUDY; LIGHT SCATTERING; LIPOPHILICITY; MALE; MICELLE; MOLECULAR MODEL; MORPHOLOGY; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PARTICLE SIZE; PROTON NUCLEAR MAGNETIC RESONANCE; RACEMIC MIXTURE; RAT; SPINAL NERVE; STOICHIOMETRY; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84872449767     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23393     Document Type: Article

References (34)

1. Xu JJ, Diaz P, Astruc-Diaz F, Craig S, Munoz E, Naguib M. 2010. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg 111(1):99-109.
2. Naguib M, Xu JJ, Diaz P, Brown DL, Cogdell D, Bie B, Hu J, Craig S, Hittelman WN. 2012. Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anesth Analg 114(5):1104-1120.
3. Naguib M, Diaz P, Xu JJ, Astruc-Diaz F, Craig S, Vivas-Mejia P, Brown DL. 2008. MDA7: A novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol 155(7):1104-1116.
4. Diaz P, Phatak SS, Xu J, Fronczek FR, Astruc-Diaz F, Thompson CM, Cavasotto CN, Naguib M. 2009. 2, 3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: Design, synthesis, and binding mode prediction through ligand-steered modeling. ChemMedChem 4(10):1615-1629.
5. Luo Z, Naguib M. 2012. A synthetic approach for (S)-(3-benzyl-3-methyl-2, 3-dihydro-benzofuran-6-yl)-piperidin-1-yl-methanone, a selective CB2 receptor agonist. Tetrahedron Lett 53(26):3316-3318.
6. Lopez-Berestein G, Tari AM, Lim S-J. 2002. Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes. PCT patent no WO2002032413.
7. Higuchi T, Connors KA. 1965. Phase solubility techniques. In: Advances in analytical chemistry and instrumentation (chapter 4); Reilley C, Ed. New York: Wiley/Interscience, pp 117-212.
8. Aree T, Schulz B, Reck G. 2003. Crystal structures of β-cyclodextrin complexes with formic acid and acetic acid. J Inclusion Phenom Macrocyclic Chem 47(1-2):39-45.
9. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. 1994. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53(1):55-63.
10. Dixon W. 1965. The up-and-down method for small samples. J Am Stat Assoc 60:967-978.
11. Brainin-Mattos J, Smith ND, Malkmus S, Rew Y, Goodman M, Taulane J, Yaksh TL. 2006. Cancer-related bone pain is attenuated by a systemically available δ-opioid receptor agonist. Pain 122(1-2):174-181.
12. Veiga MD, Merino M, Fernández D, Lozano R. 2002. Characterization of some cyclodextrin derivatives by thermal analysis. J Therm Anal Calorim 68:511-516.
13. de Araújo MrVG, Vieira EKB, Lázaro GS, de Souza Conegero L, Ferreira OP, Almeida LE, Barreto LS, da Costa Jr NB, Gimenez IF. 2007. Inclusion complexes of pyrimethamine in 2-hydroxypropyl-β-cyclodextrin: Characterization, phase solubility and molecular modelling. Bioorg Med Chem Lett 15(17):5752-5759.
14. Orgoványi J, Pöppl L, H-Otta K, Lovas GA. 2005. Characterization of some cyclodextrin derivatives by thermal analysis. J Thermal Anal Calorimetry 81:261-266.
15. Gabelica V, Galic N, De Pauw E. 2002. On the specificity of cyclodextrin complexes detected by electrospray mass spectrometry. J Am Soc Mass Spectrom 13(8):946-953.
16. Smith RD, Light-Wahl KJ. 1993. The observation of non-covalent interactions in solution by electrospray ionization mass spectrometry: Promise, pitfalls and prognosis. Biol Mass Spectrom 22(9):493-501.
17. Smith RD, Light-Wahl KJ. 1993. The observation of non-covalent interactions in solution by electrospray ionization mass spectrometry: Promise, pitfalls and prognosis. Biol Mass Spectrom 22(9):493-501.
18. Schalley CA. 2000. Supramolecular chemistry goes gas phase: The mass spectrometric examination of noncovalent interactions in host-guest chemistry and molecular recognition. Int J Mass Spectrom 194(1):11-39.
19. Djedaïni F, Lin SZ, Perly B, Wouessidjewe D. 1990. High-field nuclear magnetic resonance techniques for the investigation of a β-cyclodextrin:indomethacin inclusion complex. J Pharm Sci 79(7):643-646.
20. Loftsson T, Olafsdottir BJ, Frioriksdottir H, Jonsdottir S. 1993. Cyclodextrin complexation of NSAIDSs: Physicochemical characteristics. Eur J Pharm Sci 1(2):95-101.
21. Zornoza A, Martín C, Sánchez M, Vélaz I, Piquer A. 1998. Inclusion complexation of glisentide with α-, β- and γ-cyclodextrins. Int J Pharm 169(2):239-244.
22. Loftsson T, Brewster ME. 2010. Pharmaceutical applications of cyclodextrins: Basic science and product development. J Pharm Pharmacol 62(11):1607-1621.
23. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: Basic science and product development. J Pharm Pharmacol 62(11):1607-1621.
24. Loftsson T, Brewster ME. 2012. Cyclodextrins as functional excipients: Methods to enhance complexation efficiency. J Pharm Sci 101(9):3019-3032.
25. He Y, Fu P, Shen X, Gao H. 2008. Cyclodextrin-based aggregates and characterization by microscopy. Micron 39(5):495-516.
26. Messner M, Kurkov SV, Brewster ME, Jansook P, Loftsson T. 2011. Self-assembly of cyclodextrin complexes: Aggregation of hydrocortisone/cyclodextrin complexes. Int J Pharm 407(1-2):174-183.
27. Bittner B, Mountfield RJ. 2002. Intravenous administration of poorly soluble new drug entities in early drug discovery: The potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Discov Dev 5(1):59-71.
28. Egger-Heigold B. 2005. The effect of excipients on pharmacokinetic parameters of parenteral drugs. PhD Thesis. Basel: Basel University.
29. Dhanikula AB, Singh DR, Panchagnula R. 2005. In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of paclitaxel: Gel, film, prodrug, liposomes and micelles. Curr Drug Deliv 2(1):35-44.
30. Stella VJ, Rao VM, Zannou EA, Zia V. 1999. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 36(1):3-16.
31. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharm Rev 51(4):691-743.
32. Rouf MA. 2007. Development of Rapamycin drug delivery systems, their characterization and investigation of the antiproliferative effect on cell cultures. Health Sciences Institute, Pharmaceutical Technology. PhD Thesis. Ankara: Hacettepe University.
33. Bruzell EM, Morisbak E, Tonnesen HH. 2005. Studies on curcumin and curcuminoids. XXIX. Photoinduced cytotoxicity of curcumin in selected aqueous preparations. Photochem Photobiol Sci 4(7):523-530.
34. Ishida T, Harashima H, Kiwada H. 2002. Liposome clearance. Biosci Rep 22(2):197-224.